Skip to main content

Table 3 Comparison of demographic, laboratory, and radiological characteristics in the group 2 based on liver stiffness, with comparison to the control group treated with sorafenib

From: Predictors of residual hepatic reserve and hepatic decompensation in cirrhotic patients after ablated hepatocellular carcinoma treated by DDAs or systemic therapy

 

Study group 2 (n=250)

Control group (n=46)

P

LS 12.5-25 kPa (100)

LS >25 kPa (150)

Age

43.9 ± 2.5

45.9 ± 3.2

47.9 ± 2.9

0.001

M/F

68/32

117/33

30/16

0.141

ALT IU/L

63± 9.9

65.2± 12.4

63.1± 13.9

0.015

AST IU/L

64.9 ± 11.5

69.5 ± 7.46

54.1 ± 10.4

0.0001

Albumin (gm/dl)

3.63 ± 0.21

3.07± 0.31

4.26 ± 0.39

0.0001

γ- globulin (gm/dl)

3.76±0.21

4.23±0.26

3.33±0.34

0.0001

Total bilirubin (mg/dl)

1.18 ± 0.19

1.49 ± 0.25

0.98 ± 0.18

0.0001

Platelet count( cell/ul)

92.5 ± 11.9

78.9± 10.3

161.2 ± 13.5

0.0001

PDW/MPV

2.7 ± 0.44

3.67±0.51

1.7±0.35

0.0001

PC%

61 ± 5.7

52.4 ± 2.8

76.3 ± 6.54

0.0001

CTP

6

6

5

-

Sodium

140.5 ±2.5

134.6±4.8

140 ±3.9

0.001

Ammonia (ug/dl)

78.2±20.7

104±13.6

43.9±9.8

0.0001

Creatinine (mg/dl)

0.99±0.25

1.2±0.22

0.82±0.42

0.002

MELD

12.9 ±2

17.9±3.4

7.67±0.85

0.0001

LSM by fibroscan (kPa)

20.2 ± 2.2

29.8±2.7

8.43±0.89

0.0001

Radiological Signs

 - liver volume (ml)

614.8 ± 64.7

554 ± 90.7

1265.3 ± 86.2

0.0001

Complications (n=129)

52(40.3%)

77 (59.7%)

0

0.00001

-Hepatic decompensation (122)

52

70

-

0.0001

-upper GIT bleeding (5)

-

5

-

0.0001

-cardiomyopathy (2)

-

2

-

0.0001

  1. PDW/MPV Platelet distribution width/mean platelet volume, PC Prothrombin concentration, CTP Child Turcotte Pugh score, MELD Model for end stage liver disease, HCC Hepatocellular carcinoma, SVR Sustained virological response